BOEHRINGER INGELHEIM RCV GMBH & CO KG

Their core work

Boehringer Ingelheim RCV is the Vienna-based research center of Boehringer Ingelheim, one of the world's largest pharmaceutical companies. Their R&D activities span two distinct domains: oncology research focused on cancer metastasis and tumor dormancy mechanisms, and bioprocess engineering for producing recombinant proteins and biotherapeutics using microbial expression systems. In H2020, they primarily contributed as an industrial training host within Marie Skłodowska-Curie networks, offering early-stage researchers access to pharma-grade research infrastructure and real-world drug development expertise.

What they specialise in

How they've shifted over time

With only three projects spanning 2017–2025, evolution is modest but detectable. Their earliest involvement (META-CAN, 2017) focused on cancer metabolism and immunology, while their later projects expanded into bioprocess engineering (Secreters, 2019) and deeper mechanistic cancer biology around metastatic dormancy (Evomet, 2021). This suggests a dual-track strategy: deepening their oncology research while building parallel capabilities in biomanufacturing — both core to a pharma company's pipeline.

They are investing in understanding why cancers remain dormant then metastasize — a question with direct implications for next-generation oncology therapeutics — while simultaneously strengthening biomanufacturing capabilities.

How they like to work

Boehringer Ingelheim RCV has never coordinated an H2020 project, consistently joining as a participant or third party. This is typical for large pharma companies who contribute industrial expertise and infrastructure to academic-led training networks without taking on administrative coordination. With 47 unique partners across 13 countries, they engage in broad European consortia rather than small focused teams, reflecting the large-scale nature of MSCA training networks.

They have collaborated with 47 distinct partners across 13 countries, indicating wide European reach through MSCA training networks. Their network is broad but likely driven by the consortium structures of academic-led ITNs rather than by repeated bilateral partnerships.

What sets them apart

As a major pharmaceutical company's dedicated research center, Boehringer Ingelheim RCV offers something rare in MSCA networks: direct access to industrial drug development pipelines and pharma-scale bioprocessing facilities. For academic partners, collaborating with them means doctoral researchers get hands-on training in a real industry R&D environment. For consortium builders, they bring credibility, infrastructure, and a clear path from research to commercial application in both oncology and biotherapeutics manufacturing.

Highlights from their portfolio

• Evomet
  Tackles the critical clinical question of how cancers evolve to metastasize, combining tumor dormancy, stroma interactions, and latency — directly relevant to Boehringer Ingelheim's oncology pipeline.
• Secreters
  Addresses industrial biomanufacturing challenges with next-generation microbial expression hosts, bridging academic systems biology with commercial protein production at scale.